Search results for "Non-Small-Cell Lung"

showing 5 items of 205 documents

Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.

2007

Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40…

medicine.medical_specialtyLung Neoplasmsmedicine.drug_classAdministration OralPharmacologyVinorelbineVinblastineRoute of administrationchemistry.chemical_compoundOral administrationCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsMedicineAntiemeticHumansPharmacology (medical)Randomized Controlled Trials as Topicbusiness.industryCombination chemotherapyVinorelbineAntineoplastic Agents PhytogenicCombined Modality TherapyGemcitabineCarboplatinBioavailabilitySurgerychemistryOral vinorelbine small cell lung cancer.businessmedicine.drugDrugs
researchProduct

A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy

2006

Guillain-Barré Syndrome (GBS) is a demyelinating polyneuropathy of probable autoimmune pathogenesis characterized by rapidly progressive symmetric paralysis. In the literature some cases of GBS associated with anticancer chemotherapy are reported. We present a case of a 55-year old woman who complained of progressive motor deficit in four limbs, areflexia in lower limbs and facial nerve paralysis one week after beginning cisplatin-gemcitabine chemotherapy for metastatic lung cancer. The cerebrospinal fluid analysis showed a strong positive Pandy reaction with 435 mg/dl total protein. The electromyography and the electroneuronography established the diagnosis of inflammatory demyelinating po…

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentBone NeoplasmsGuillain-Barre SyndromeDeoxycytidineGastroenterologyPathogenesisCerebrospinal fluidCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsElectroneuronographyParalysismedicineHumansPharmacology (medical)Lung cancerPharmacologyChemotherapyGuillain-Barre syndromebusiness.industryGuillain-Barré Syndrome neuropathy chemotherapy toxicity lung cancerImmunoglobulins IntravenousMiddle Agedmedicine.diseaseGemcitabineFacial nerveSurgeryInfectious DiseasesOncologyFemaleCisplatinmedicine.symptombusiness
researchProduct

Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofraction…

2020

Objectives: To investigatewhether assessmentwith two geriatric screening tools shows a correlationwith clinical outcomes of patients aged 65 years or more, with early-stage Non-Small Cell Lung Cancer (es-NSCLC) treated with hypofractionated stereotactic radiotherapy. Methods: FromMarch 2014 to June 2018we retrospectively evaluated 42 patientswith stage I and II lung tumors. Patients were assessed with Charlson Comorbidity Index (CCI) and G8 screening tool. Median age was 74 years (range, 65–91). Stereotactic radiotherapy was performed with Helical Tomotherapy delivering 50–70 Gray (Gy) in 8–10 fractions. Toxicity was evaluated using Common Terminology Criteria for Adverse Events v4.0 criter…

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentRadiosurgeryChest painTomotherapySettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungmedicineHumansProspective Studies030212 general & internal medicineStage (cooking)Adverse effectProspective cohort studyLung cancerEarly Detection of CancerAgedRetrospective StudiesLung cancer Radiation therapy G8 Charlson comorbidity indexbusiness.industryCommon Terminology Criteria for Adverse EventsPrognosismedicine.diseaseTreatment OutcomeOncology030220 oncology & carcinogenesisCohortDose Fractionation RadiationRadiologyGeriatrics and Gerontologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessJournal of Geriatric Oncology
researchProduct

Plausible Role of Estrogens in Pathogenesis, Progression and Therapy of Lung Cancer

2021

Malignant neoplasms are among the most common diseases and are responsible for the majority of deaths in the developed world. In contrast to men, available data show a clear upward trend in the incidence of lung cancer in women, making it almost as prevalent as breast cancer. Women might be more susceptible to the carcinogenic effect of tobacco smoke than men. Furthermore, available data indicate a much more frequent mutation of the tumor suppressor gene-p53 in non-small cell lung cancer (NSCLC) female patients compared to males. Another important factor, however, might lie in the female sex hormones, whose mitogenic or carcinogenic effect is well known. Epidemiologic data show a correlatio…

p53MaleLung NeoplasmsHealth Toxicology and Mutagenesismedicine.medical_treatmentlcsh:MedicineEstrogen receptorReviewNSCLCsex hormonessex hormone03 medical and health sciences0302 clinical medicineBreast cancerA549Carcinoma Non-Small-Cell LungmedicineCarcinomaestrogenNeoplasmEstrogen Receptor betaHumansLung cancerCarcinogennon-small cell lung cancer030304 developmental biology0303 health sciencesLungbusiness.industrylcsh:RPublic Health Environmental and Occupational Health17β-estradiolEstrogen Receptor alphaHormone replacement therapy (menopause)Estrogensmedicine.diseaselung adenocarcinomarespiratory tract diseaseslung cancermedicine.anatomical_structure17- estradiolReceptors Estrogen030220 oncology & carcinogenesisCancer researchFemalebusinessestrogen receptorInternational Journal of Environmental Research and Public Health
researchProduct

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitab…

2007

trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer
researchProduct